Navigation Links
NaZura BioHealth Spun-out from Elcelyx Therapeutics to Advance Lovidia for Weight Management
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that it has formed NaZura BioHealth, a separate company established to focus on the development of Gut Sensory Modulators (GSM) including lead product Lovidia™, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet™, the company's proprietary delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

(Logo: http://photos.prnewswire.com/prnh/20130904/LA73683LOGO)

"We are separating the Lovidia and NewMet assets in order to maximize their value as we approach critical development milestones," said Alain D. Baron, M.D., president and chief executive officer of both NaZura BioHealth and Elcelyx Therapeutics. "NaZura BioHealth will commercialize Lovidia, a one-of-a-kind weight loss product with launch planned for early second quarter 2014, and Elcelyx Therapeutics will continue to advance NewMet for Type 2 diabetes."

Lovidia, a dietary supplement, is being developed with the level of rigor typical of pharmaceutical products. An early Lovidia prototype demonstrated statistically significant and progressive weight loss through 16 weeks in a randomized, placebo-controlled, double-blind clinical study. In 121 evaluable overweight or obese subjects, three times as many people lost 5% of their body weight compared to placebo. This was accomplished without diet or exercise modification and the tolerability and safety profile of the prototype was similar to placebo. In other short-term studies, preliminary formulations of Lovidia increased the body's food-driven production of natural satiety and gluco-regulatory gut hormones twofold; with the same number of calories, subjects had twice the satiety signal.

An optimized version of Lovidia is now being readied for market. It is expected that this optimized product will produce greater weight loss than that seen with the prototype. A 16-week clinical study using the optimized Lovidia product is now underway. This placebo-controlled, double-blind weight loss study in 240 overweight and obese subjects is fully enrolled with results expected in the fourth quarter of 2013.

Lovidia is a proprietary mix of dietary ingredients designated by the U.S. Food and Drug Administration as Generally Recognized as Safe (GRAS) and FDA-approved food additives.

NaZura BioHealth and Elcelyx Therapeutics share the same board of directors, including Ralph Christoffersen, Ph.D., Morgenthaler Ventures (chairman); Alain D. Baron, M.D.; Rick Barry, GSM Fund LLC; Brook Byers, Kleiner Perkins Caufield & Byers; Jim Glasheen, Ph.D., Technology Partners; Ginger L. Graham, former President and CEO, Amylin Pharmaceuticals.

About NaZura BioHealth, Inc.
NaZura BioHealth is developing consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) technology. GSMs are delivered to the lower gut where they intensify the body's natural food-driven signals that trigger a sense of fullness and facilitate glucose regulation. NaZura plans to commercialize its lead product, Lovidia™, a dietary supplement for weight management, in early second quarter 2014. For more information, visit www.NaZuraBio.com.

About Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet™ for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity.  Elcelyx is based in San Diego, CA. For more information, visit www.Elcelyx.com.


'/>"/>
SOURCE NaZura BioHealth, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
2. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
3. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
4. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
5. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
6. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
7. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
8. PTC Therapeutics to Present at Upcoming Investor Conferences
9. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
10. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
11. Echo Therapeutics Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):